Brief: Valbiotis: Positive Results Of Clinical Study On Bioavailability And Mode Of Action Of Totum•070 Against Hypercholesterolemia

Valbiotis SA

29/03/2022 06:39

March 29 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE POSITIVE RESULTS OF ITS CLINICAL
STUDY
ON THE BIOAVAILABILITY AND MODE OF ACTION OF TOTUM•070, AGAINST
HYPERCHOLESTEROLEMIA
    * PHASE II HEART CLINICAL EFFICACY STUDY RESULTS TO BE
COMMUNICATED IN Q2 OF 2022, PRIMARY ENDPOINT BEING REDUCTION OF
BLOOD LDL-CHOLESTEROL
    * METABOLOMIC ANALYSIS CONFIRMS THE PRESENCE OF 22
METABOLITES OF
INTEREST IN THE SERUM OF VOLUNTEERS AFTER ORAL INGESTION OF 5G
OF TOTUM•070
    * DATA CONFIRM THIS ACTIVE SUBSTANCE'S POTENTIAL FOR
REGULATING
CHOLESTEROL METABOLISM IN HUMANS
    * TOTUM•070: THIS IS A POSITIVE CLINICAL DEVELOPMENT AND A
VERY
ENCOURAGING SIGN WHILE WE WAIT FOR PHASE II HEART CLINICAL
EFFICACY RESULTS, WHICH WILL BECOME AVAILABLE IN Q2 OF 2022

Source text for Eikon:  ID:nBw1Xdyb8a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))